Loan and series B plug finance hole as to-BBB begins Phase I/II brain cancer trial
This article was originally published in Scrip
Executive Summary
The private Dutch biotechnology company to-BBB is poised to start a Phase I/II trial of its lead brain cancer compound, 2B3-101, in June after securing a government loan of €1.2 million.